Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

LILLY RECEIVES MHRA MARKETING AUTHORISATION FOR ABEMACICLIB (VERZENIOS®▼) IN COMBINATION WITH ENDOCRINE THERAPY FOR ADJUVANT TREATMENT OF People with HR+, HER2- HIGH RISK EARLY BREAST CANCER

   318
LILLY RECEIVES MHRA MARKETING AUTHORISATION FOR ABEMACICLIB (VERZENIOS®▼) IN COMBINATION WITH ENDOCRINE THERAPY FOR ADJUVANT TREATMENT OF People with HR+, HER2- HIGH RISK EARLY BREAST CANCER

Eli Lilly and Company announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation (MA) for abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence. 

BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca

   369
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca

  • Second novel target for idiopathic pulmonary fibrosis was discovered using BenevolentAI’s drug discovery platform and selected for AstraZeneca’s drug development portfolio

  • A total of three targets have been selected for portfolio-entry in the collaboration to date, with the potential to generate further future development milestones and sales based royalty revenues for BenevolentAI

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

   248
DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research  in dengue

BenevolentAI, a leading clinical-stage artificial intelligence (AI) enabled drug discovery company, and Drugs for Neglected Disease initiative (DNDi), a not-for-profit research and development (R&D) organisation focusing on neglected diseases, today announced they have begun a joint research project to tackle dengue, one of the world’s most prevalent infectious diseases. 

Pharmapack Europe: Education, Innovation and Networking

   226
Pharmapack Europe: Education, Innovation and Networking

The last year has been a hugely exiting time for pharma with the industry continuing to take centre stage globally with record levels of innovation and the successful rollout of Covid vaccines and boosters. But looking a little further ahead, areas like the use of mRNA outside of covid vaccines could potentially bring in a new wave of potential opportunities in the drug device and delivery space. Smart Packaging innovations are also generating much excitement and environmental advancements have seen an accelerated rate of adoption and new ground is being broken daily.

Hataali wins US patent for the use of blockchain in advanced medicinal therapy products

   205
Hataali wins US patent for the use of blockchain in advanced medicinal therapy products

ATMPS Ltd/Hataali – the leader in blockchain-based data sharing platforms for advanced therapies – announces it has been granted a patent from the United States Patent and Trademark Office (USPTO) for the use of blockchain technologies in personalised medicines. The company also has applications pending in both Europe and Asia as it looks to cement its technological advantage in the rapidly growing advanced therapy space globally.

Japan tops CPhI ‘API Quality’ ranking for second year

   217
Japan tops CPhI ‘API Quality’ ranking for second year

Tokyo, 11 March 2022: CPhI Japan 2022 returns as a SMART event – with live exhibition at the Big Sight Exhibition Center in Tokyo (20-22 April) alongside an online networking platform – as CPhI data[1] confirms the country continues to top global ‘API quality’ rankings, with Japanese respondents bullish on growth in 2022 forecasting a CAGR of 14% on average. The country, despite the global challenges of the last year, also increased its ‘overall competitiveness’ score by 2%, while ranking narrowly behind only Germany and the USA for the quality of its ‘finished product manufacturing’ (8.28) and ‘innovativeness for solid dose’ (7.39).

Emmes Acquires Casimir, Its Fourth Major Acquisition

   228
Emmes Acquires Casimir, Its Fourth Major Acquisition

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it has acquired Casimir, a U.S.-based CRO. Casimir has experience in more than 20 rare diseases and has worked with regulators, sponsors and patients to develop outcome measures that capture the nuances of disease progression and treatment benefit.

Aragen acquires Intox Pvt. Ltd

   182
Aragen acquires Intox Pvt. Ltd

Aragen Life Sciences, a global research, development, and manufacturing solutions provider (CRO/CDMO), announced that it has signed a definitive agreement to acquire Pune-based Intox Pvt. Ltd.